RSV is the leading cause of
hospitalization in all infants and can be
especially dangerous for infants and
children with certain conditions.
Each year in the United States, an estimated
60,000-80,000 children younger than 5 years are hospitalized due to RSV infection.
There are two effective ways to
prevent RSV in your infant:
A maternal RSV vaccine (Abrysvo) can be given to pregnant persons during 32-36 weeks of pregnancy. Pregnant persons can then transfer that protection to infants for their first 6 months of life.
monoclonal antibody product, called nirsevimab (Beyfortus), can
be given to protect infants aged <8 months who are born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk for severe RSV disease and are entering their second RSV season.
RSV Vaccine for Pregnant People to
Protect Newborn Infants
An RSV vaccine called Abrysvo is recommended if you are 32-36 weeks pregnant during September through January.
When pregnant people receive this vaccine, RSV protection for their infant starts as soon as the baby is born and will last until they are at least 6 months old.
Pregnant persons can get the RSV vaccine (Abrysvo) at the same time as other vaccines that are recommended during pregnancy to protect newborns, including Tdap, COVID-19, and Influenza.
RSV Immunization for Infants (Preventive Monoclonal Antibodies)
If mom received the RSV vaccine during pregnancy:
Most infants who are born to mothers
who got the RSV vaccine at least 2
week before giving birth will not
need additional RSV immunization.
If mom did
not receive RSV
vaccine during pregnancy at
least 2 weeks before delivery, than infants should get an RSV antibody immunization called nirsevimab (Beyfortus) during RSV season (October-March).
Infants born between October to March should get a dose of nirsevimab (Beyfortus) within one week of birth.
Infants younger than 8 months are eligible to get nirsevimab (Beyfortus), but because of a shortage in doses, infants younger than 6 months of age, American Indian and Alaska Native, and infants with conditions that put them at higher risk of severe disease should be prioritized.
Infants and children 8-19 months of age who are at
high risk for severe RSV disease and entering their second RSV season should also receive one dose of nirsevimab or palizuvimab.
Monoclonal antibody products provide an extra layer of protection against RSV disease.
Adults 60 Years of Age and Older
Each year in the U.S., between 60,000-160,000 older adults are hospitalized and 6,000-10,000 die due to RSV infection.
Note: PDF documents on this site were created using Adobe Acrobat 5.0 or later. Document functionality may be reduced if you are using an earlier version (4.x or less).
Get the latest version of Adobe Acrobat.
Public Health has made reasonable efforts to provide accurate translation. However, no computerized translation is perfect and
is not intended to replace traditional translation methods. If questions arise concerning the accuracy of the information, please refer to the English edition
of the website, which is the official version.